Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FL1GZ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,375
Award facts
- Contract value 100% obligated
- $28,375.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $28,375.12 firm fixed-price delivery order to Amerisourcebergen Drug Corp (UEI: KABZK8W6PQT3) on January 28, 2026, for the supply of DUPIXENT 300 mg/2 mL pens. This non-set-aside contract represents a task order under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. Amerisourcebergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing critical medical supplies to military and federal healthcare systems. The company's parent organization is Cencora, Inc. (UEI: NWEGNLYTBDW4), which operates under the Amerisourcebergen brand and holds the primary IDC with DLA.
This delivery order is part of the DLA's comprehensive pharmaceutical supply chain operations, which ensure that military treatment facilities, veterans' healthcare programs, and other federal medical institutions have access to essential brand-name and generic medications across multiple therapeutic domains. DUPIXENT (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic conditions, reflecting the breadth of specialized pharmaceuticals procured through this contract vehicle. The award was competitively executed with an ultimate completion date of January 29, 2026, demonstrating the rapid fulfillment capability required for federal medical procurement operations.
Quick answers
Who was awarded contract SPE2DR26FL1GZ?
SPE2DR26FL1GZ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FL1GZ worth?
The government has obligated $28,375 on SPE2DR26FL1GZ.
Is contract SPE2DR26FL1GZ an order under another contract?
Yes. SPE2DR26FL1GZ is a delivery order under SPE2DR25D3401, an indefinite delivery contract.
Was contract SPE2DR26FL1GZ competed?
The extent of competition for SPE2DR26FL1GZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award